miRNAs 在喉癌患者中的预后价值：系统评价和荟萃分析。
Prognostic Value of MiRNAs in Patients with Laryngeal Cancer: A Systematic Review and Meta-Analysis.
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China.
Department of Pathogenic Biology, School of Basic Medicine, Southwest Medical University, Luzhou, Sichuan, China.
出版信息
Curr Cancer Drug Targets. 2020;20(10):802-810. doi: 10.2174/1568009620666200806094709.
BACKGROUND
Many studies have explored the relationship between the expression level of miRNAs and the prognosis of patients with laryngeal cancer (LC). However, the prognostic value of miRNA in LC patients has not been comprehensively evaluated.
METHODS
PubMed, Web of Science, Embase, and Cochrane Database of Systematic Reviews were extensively searched for all studies published before the end of February 2020 that investigated the correlation between miRNA expression level and clinical prognosis in patients with LC.
RESULTS
Twenty-one studies involving 1784 patients were included in our meta-analysis. The survival endpoints of OS and DFS were 1.69 (95% CI 1.45-1.98; p < 0.05) and 3.62 (95% CI 2.34-5.62; p < 0.05), respectively. Both OS and DFS results were statistically significant. Subgroup analyses were performed by evaluating the effects of miR-196b, miR-375, and miR-21 on OS and the effects of miR-34c-5p on DFS. The results obtained for miR-196b and miR-34c-5p were statistically significant.
CONCLUSION
The results indicate that miRNAs, as prognostic biomarkers for LC, play an important role in clinical value. In particular, miR-196b and miR-34c-5p have the potential to be used as prognostic biomarkers. However, further large-scale cohort studies based on these miRNAs are urgently needed to validate their clinical value and help determine the direction of future clinical work in the area.
背景
许多研究探讨了 miRNA 的表达水平与喉癌（LC）患者预后之间的关系。然而，miRNA 在 LC 患者中的预后价值尚未得到全面评估。
方法
全面检索了 PubMed、Web of Science、Embase 和 Cochrane 系统评价数据库，以获取截至 2020 年 2 月底所有探讨 LC 患者 miRNA 表达水平与临床预后相关性的研究。
结果
纳入了 21 项包含 1784 例患者的研究进行荟萃分析。OS 和 DFS 的生存终点分别为 1.69（95%CI 1.45-1.98；p<0.05）和 3.62（95%CI 2.34-5.62；p<0.05）。OS 和 DFS 结果均具有统计学意义。通过评估 miR-196b、miR-375 和 miR-21 对 OS 的影响以及 miR-34c-5p 对 DFS 的影响进行了亚组分析。miR-196b 和 miR-34c-5p 的结果具有统计学意义。
结论
结果表明，miRNA 作为 LC 的预后生物标志物，具有重要的临床价值。特别是 miR-196b 和 miR-34c-5p 具有作为预后生物标志物的潜力。但是，迫切需要基于这些 miRNA 的大规模队列研究来验证它们的临床价值，并有助于确定未来临床工作的方向。
Zotero 插件